Kornimate/medical-research-clean huggingface dataset:
arterial stiffness in patients with sepsis

Conditions: the Arterial Stiffness

Summary: to investigate whether arterial stiffness, as defined by measuring pulse wave velocity, could be identified as an independent risk factor for development of acute kidney injury in sepsis. to compare between the pulse wave velocity and shear wave ultrasound elastography (swe) as a different methods of evaluation of arterial stiffness in prediction of acute kidney injury in sepsis.

demographic and historical data: the patient age, sex, history of hypertension, diabetes ,peripheral vascular disease , ihd, source of sepsis and indication of mechanical ventilation if indicated. clinical examination data: pulse, blood pressure, respiratory rate, temperature and thorough chest, cardiac and neurological examination data will be obtained. volume state of the patient: cvp measurement, input and output fluid chart. investigation : cbc( neutrophil count, neutrophil/lymphocyte ratio), blood urea and serum creatinine ,serum electrolytes, serum lactate,serum albumin,crp ,coagualtion profile and lipid profile. sequential organ failure assessment (sofa) score, acute physiology and chronic health evaluation (apache ii) score, and complete sepsis workup to identify the possible sources of sepsis. 12 lead ecg and echocardiographic data that include: left and right atrial dimensions. the left ventricular ejection fraction will be assessed by the simpson method, left ventricular diastolic function will be assessed by measuring velocities of the mitral e and a waves and of the e' wave of the external mitral annulus and by calculating the e/e' ratio. right ventricle dimension and dysfunction will be evaluated by tapse and pulmonary artery acceleration time. pulmonary artery pressure will be measured from tricuspid flow if possible. pulse wave velocity (pwv), a measurement of arterial stiffness, will be assessed at the systemic region (carotid-femoral pwv), which is the gold standard method. in the first 24 hours of admission. the two-dimensional swe technique will be used in our study , an imaging method will be obtained by simultaneously applying multiple arfi waves into the tissue and measuring the resulting shear waves .it will be assessed in the first 24 hours of admission. rri will be measured at the time of admission. all measurements will be performed by the same examiner and repeated by an independent blinded operator. using pulse-wave doppler, an interlobar or arcuate artery will be selected. rri will be calculated as the equation "(psv-edv)/psv". the means of three distinct rri calculations will be recorded.

Eligibility criteria:
inclusion criteria: * adult patients who admitted to critical care unit of internal medicine department with sepsis after obtaining consent. exclusion criteria: * children below 18 yr. * patients could not be scanned within 24-h after icu admission. * patients with end stage renal disease or transplanted kidney. * patients with renal artery stenosis, and obstructive uropathy
exemestane as treatment in neoadjuvant setting for operable breast cancer patients

Conditions: Breast Neoplasms

Summary: to evaluate clinical and pathologic response rates following primary hormonal therapy by exemestane (aromasin®)


Eligibility criteria:
inclusion criteria: * post-menopausal patients with unilateral breast cancer t2 to t4, n0-1, m0, non inflammatory, operable, hormonal receptors positive exclusion criteria: * patients with bilateral breast cancer t4d, inflammatory, non operable, hormonal receptors negative
serum antimullerian hormone levels in patients who underwent uterine artery ligation

Conditions: Uterine Artery Ligation; Ovarian Reserve

Summary: investigators would like to see the amh values after uterine artery ligation

group/cohort: uterine artery ligation (ual) investigators would like to invite the patients to the hospital at least 6 months after surgery who underwent only uterine artery ligation performed due to uterine atony during c-section. participants would be evaluated for their ovarian reserve via hormones and antral follicle count (afc) control group: investigators would like to invite the patients to the hospital at least 6 months after c-section who delivered baby without any complication. participants would be also evaluated for their ovarian reserve via hormones and antral follicle count (afc)

Eligibility criteria:
inclusion criteria: * age 18- 35 years * no systemic or endocrine diseases * patients who had uterine artery ligation due to atony * healthy postpartum patients as controls exclusion criteria: * patients with pcos * pregnancy with ivf or oosit donation * patients with endocrinopathy, diseases which require radiotherapy and chemotherapy etc. * patients with bmi \>40

Keywords: uterine atony amh
impact of humira® therapy on ocular inflammation, selected health care resource utilization and patient reported outcomes in patients with active non-infectious intermediate, posterior and panuveitis in routine clinical practice

Conditions: Uveitis

Summary: this study aims at evaluating real life effectiveness of originator adalimumab (humira®) participants with active non-infectious intermediate, posterior and panuveitis (niippu) despite high-dose corticosteroid therapy; including effect on ocular inflammation, health-related quality of life, health resource utilization, work ability and medication burden, as well as describe the characteristics of niippu participants treated with humira® in the real-life setting.


Eligibility criteria:
inclusion criteria: * participants voluntarily signed a patient authorization form to use and disclose personal health information (or informed consent, where applicable). * age \>= 18 years at the time of the enrollment. * diagnosis of active niipp uveitis as defined by the presence of at least 1 of the following parameters: 1. active, inflammatory, chorioretinal and/or inflammatory retinal vascular lesion 2. \>= 2+ anterior chamber cells \[standardization of uveitis nomenclature (sun) criteria\] 3. \>= 2+ vitreous haze \[national eye institute (nei)/sun criteria\] * humira® treatment is indicated as per local summary of product characteristics (smpc) and professional and/or reimbursement guidelines. * decision on the treatment with humira® was made prior to any decision to approach the patient to participate in this study. exclusion criteria: * participants who cannot be treated with humira® according to the local humira® smpc and/or local professional and reimbursement guidelines. * prior treatment with humira®, including current course of humira® started prior to baseline visit assessments. * participants currently participating in other clinical research. * participants who are unwilling or unable to complete the quality of life and other patient reported questionnaires.

Keywords: humira® adalimumab ocular inflammation active non-infectious intermediate, posterior and panuveitis
efficacy of k-y jelly in prevention of postoperative sore throat after nasal surgery

Conditions: Postoperative Sore Throat

Summary: postoperative sore throat (post) is a fairly common side effect of general anesthesia which is caused by the mucosal injury and nerve compression associated with tracheal intubation or laryngeal mask airway device insertion. in this randomized study, the authors evaluate the effect of k-y jelly-soaked nasopharyngeal packs on post and postoperative nausea and vomiting in patients subjected to nasal surgery.

postoperative sore throat (post) is a fairly common side effect of general anesthesia which is caused by the mucosal injury and nerve compression associated with tracheal intubation or laryngeal mask airway device insertion. in this randomized study, the authors evaluate the effect of k-y jelly-soaked nasopharyngeal packs on post and postoperative nausea and vomiting in patients subjected to nasal surgery. the present double-blinded randomized controlled study was conducted at al-azhar university hospitals, cairo, egypt. the study protocol was approved by the local ethical committee of al-azhar faculty of medicine and all patients provided informed consent before enrollment in the study.

Eligibility criteria:
inclusion criteria: * patients submitted to nasal surgery under general anesthesia. exclusion criteria: * acute of chronic nasopharyngeal conditions, * gastroesophageal reflux, regurgitation, * history of postoperative sore throat, * nasal surgery for malignant disease, * concurrent or recent use of systemic or topical agents used for sore throat or * mallampati grade more than 2.
epigenetics and psychoneurologic symptoms in women with breast cancer

Conditions: Breast Cancer

Summary: this study examines the relationship among epigenetic alterations and the development and persistence of psychoneurologic symptoms (cognitive dysfunction, depressive symptoms, anxiety, fatigue, sleep disturbance, and pain) in women receiving chemotherapy for early stage breast cancer. the relationship among inflammatory markers and psychoneurologic symptoms will also be explored. it is hypothesized: 1. chemotherapy triggers inflammatory activation, which in turn leads to the acquisition of genetic alterations. these alterations result in cellular changes and are modified over time. 2. inflammatory activation and epigenetic alterations are related to the temporal development, severity, and persistence of psychoneurologic symptoms.

advancements in breast cancer have resulted in increased survival rates; however, many women with breast cancer experience distressing symptoms. inflammatory activation and epigenetic alterations have been associated with the etiology of cancer. to date, no investigators have considered these epigenetic processes as possible mechanisms associated with the etiology of distressing symptoms in women with breast cancer. the specific aims of this study are to examine: 1. the frequency and severity of psychoneurological (pn) symptoms (depressive symptoms, anxiety, sleep disturbances, fatigue, pain and cognitive dysfunction)and the interrelationship among pn symptoms at each time point 2. levels of inflammation and to quantify the frequency and genome-wide location of changes in epigenetic patterns across time following chemotherapy 3. the relationship among inflammation, epigenetic changes, and the development, severity, and persistence of pn symptoms across time the study results may potentially deepen understanding regarding the biological processes underlying pn symptoms and lead to improved strategies for symptom management in women with breast cancer.

Eligibility criteria:
inclusion criteria: * at least 21 years of age * diagnosed with stage i to iiia breast cancer * scheduled to receive chemotherapy exclusion criteria: * previous cancer history * previous chemotherapy history * dementia * active psychosis

Keywords: epigenetics inflammatory psychoneurologic symptoms cognitive dysfunction pain fatigue sleep disturbance depression depressive symptoms anxiety breast cancer
a study to investigate the efficacy and safety of ivonescimab combined with irinotecan liposome as second-line regimen for es-sclc

Conditions: Extensive-stage Small-cell Lung Cancer

Summary: this is an open-label, single-arm, prospective phase 2 study, evaluating the efficacy and safety of ivonescimab combined with irinotecan liposome for relapsed extensive stage small cell lung cancer, who progressed on pd-(l)1 -based first-line therapy.

patients will receive ivonescimab at 20mg/kg intravenously, on days 1 of every 21-day cycle and irinotecan liposome 56.5mg/m\^2 intravenously, on days 1 of every 14-day cycle. treatment will be discontnued in case of until the toxicity became intolerable, the investigator determined that there was no further clinical benefit (based on a combination of recist v1.1 imaging assessment and clinical status), 24 months of treatment was completed, or the study was withdrawn for other reasons.

Eligibility criteria:
inclusion criteria: 1. 18 to 75 years old (at the time of inform consent obtained). 2. be able and willing to provide written informed consent and to comply with all requirements of study participation (including all study procedures). 3. histologically or cytologically confirmed es-sclc (per the veterans administration lung study group \[valg\] staging system). 4. eastern cooperative oncology group (ecog) performance status of 0 or 1. 5. life expectancy of at least 3 months. 6. es-sclc who failed first-line platinum-based chemotherapy with checkpoint inhibitors. 7. at least one measurable tumor lesion according to recist v1.1. 8. adequate organ function. 9. all female and male subjects of reproductive potential must agree to use an effective method of contraception, as determined by the investigator, during and for 120 days after the last dose of study treatment. exclusion criteria: 1. patients with other cancer in 5 years. 2. undergone anti-angiogenic therapy prior to the first dose of study treatment. 3. evidence and history of severe bleeding tendency. 4. history of severe active autoimmune disease that has required systemic treatment in the past 2 years, severe drug allergy or have known allergy to any component of the study drugs. 5. active central nervous system (cns) metastases. 6. active infection requiring systemic therapy. 7. current presence of uncontrolled pleural, pericardial, and peritoneal effusions. 8. active hepatitis b/c, or hiv infection. 9. history of myocardial infarction, unstable angina, cardiac or other vascular stenting, angioplasty, or surgery within 12 months prior to day 1 of study treatment. 10. history of allogeneic hematopoietic stem cell transplantation or allogeneic organ transplantation. 11. history of alcohol abuse, psychotropic substance abuse or drug abuse. 12. pregnant or lactating women. 13. other conditions considered unsuitable for this study by the investigator.
hcq on par-4 levels in patients with resectable solid tumors

Conditions: Solid Tumor

Summary: baseline levels of par-4 secreted by normal cells are generally inadequate to cause massive apoptosis in cancer cells and drugs that bolster the secretion of par-4 would constitute an important therapeutic advance.the apoptosis sensitizing features of hydroxychloroquine enhance the anti-tumor effects of a broad range of cancer therapeutics. the investigators hypothesize that hydroxychloroquine will induce at least 2-fold increase in systemic (plasma) par-4 levels compared to pre-treatment plasma levels in patients with resectable solid tumors.


Eligibility criteria:
inclusion criteria: * patients must have a histologically confirmed solid tumor that is planned for surgical resection. * age ≥18 years. * ecog performance status ≤2 (karnofsky ≥60%, see appendix a). * patients must be able to ingest oral medications. * patients must have normal organ and marrow function as defined below: * absolute neutrophil count ≥1,500/mcl * platelets ≥100,000/mcl * total bilirubin less than 1.5 x uln * ast(sgot)/alt(sgpt) ≤2.5 × institutional upper limit of normal * creatinine within normal institutional limits or creatinine clearance ≥60 ml/min/1.73 m2 for patients with creatinine levels above institutional normal. * patients must be able to undergo surgical resection of their tumor as determined by the treating surgeon. * women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. * ability to understand and the willingness to sign a written informed consent document. exclusion criteria: * patients with metastatic cancer and/or cancer that is not amenable to surgery. * patients with significant malabsorption as determined by the treating physician. * patients who are receiving any other investigational agents. * patients with known brain metastases are excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. patients with primary brain tumors amenable to surgery are allowed on this protocol. * history of allergic reactions attributed to compounds of similar chemical or biologic composition to hydroxychloroquine. * uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * pregnant women are excluded from this study. * hiv-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with hydroxychloroquine. in addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. * patients that are on enzyme-inducing anti-epileptic medications

Keywords: cancer surgery hydroxychloroquine
outcome of sub-inguinal varicocelectomy on normal semen in patients complaining of orchilagia with normal semen

Conditions: Varices; Cord

Summary: varicoclelectomy is done for subfertiltiy and varicocele induced orchialgia. the effect of varicocelectomy on semen analysis is controversial. many articles report favorable outcomes and others do not. most study don't focus on varicocelectomy done for varicocele induced orchialgia,and those studies dont report on postoperative semen. this study will focus on the effect of operation on the semen postoperatively .


Eligibility criteria:
inclusion criteria: 1. primary varicocele. 2. patient's age more than 20 years. 3. scrotal pain (after exclusion of other causes). 4. normal semen analysis exclusion criteria: 1. secondary varicocele. 2. recurrent varicocele.
infrared non-cutting laser therapy for acne

Conditions: Acne Vulgaris

Summary: the purpose of this research project is to study the effect of non-ablative (non-cutting) laser therapy, a technique that uses laser energy to try to improve the appearance of the skin. in this study, we are interested in learning how well such a laser works to improve the symptoms of acne. the laser used in this particular study will be the cooltouch ii® laser, manufactured by icn photonics, inc., and has not been fda-approved for the treatment of acne.

the purpose of this research project is to study the effect of non-ablative (non-cutting) laser therapy, a technique that uses laser energy to try to improve the appearance of skin. this type of laser treatment creates changes in a layer of the skin called the dermis without causing an open wound in the skin. it is not yet clear how much improvement can be seen with these treatments or exactly how the skin's response causes these improvements. in this study, we are interested in learning how well such a laser works to improve the symptoms of acne. the laser used in this particular study will be the cooltouch ii® laser, manufactured by icn photonics, inc., and has not been fda-approved for the treatment of acne.

Eligibility criteria:
inclusion criteria: * age 13 years or older of either gender and of any racial/ethnic group. * subjects must have clinically evident acne vulgaris of the facial skin. * subjects must understand and sign the informed consent prior to participation. * subjects must be in generally good health. * subjects must be able and willing to comply with the requirements of the protocol. * you must live within a reasonable driving distance of ann arbor, michigan, and/or be able to attend all of the scheduled appointments during the study. exclusion criteria: * oral retinoid (accutane) use within 1 year of entry into the study. * systemic acne therapies (oral antibiotics) within 4 weeks of entry into the study. * topical acne therapies (retinoids, antibiotics) within 2 weeks of entry into the study. * microdermabrasion or superficial chemical peels at the sites to be treated within 3 months of entry into the study. * subjects with a history of dermabrasion or laser resurfacing at the sites to be treated. * use of topical lipid absorbing substances (clinac ac) within 2 weeks of entry into the study. * non-compliant subjects. * subjects with a significant medical history or concurrent illness/condition which the investigator(s) feel is not safe for study participation. * subjects using alcohol-based topical solutions or "exfolliating" agents within 2 weeks of entry into the study. * subjects with a history of very frequent herpes simplex infections of the face or with clinical evidence of active herpes simplex infections. * history of keloid scar formation for subjects undergoing biopsies. * pregnant or nursing females.

Keywords: acne laser
structural heat adaptation and education in urban setting

Conditions: Heat Illness

Summary: this study aims to understand whether simple, low-cost interventions, such as improved home cooling, practical advice, and minor home modifications, can help protect people's health during periods of extreme heat in densely populated, low-income neighborhoods of karachi, pakistan. key questions the study seeks to answer: 1. can these interventions reduce heat-related health problems such as dizziness, headaches, and heatstroke? 2. can they lower indoor temperatures and improve sleep quality, comfort, and daily functioning? to answer these questions, researchers will compare communities where families receive heat-related support and information with similar communities that do not, to assess any differences in health and well-being. what participants can expect: * answer questions about their health, living conditions, and how they cope with heat * have small temperature sensors placed inside their homes * some participants may wear a lightweight wristband that tracks sleep and heart rate * in selected households, cooling improvements will be made, such as adding shade, applying reflective roof paint, or enhancing airflow purpose: this study seeks to identify affordable and effective strategies to help families stay safe during extreme heat, and to use these insights to support other vulnerable communities facing similar challenges.


Eligibility criteria:
inclusion criteria: * all households within the selected clusters who provide consent. exclusion criteria: * households planning to move away from the study site within the next 6 months * individuals with severe mental or physical health conditions that preclude participation

Keywords: heat illness behaviour modification personal cooling structural modification heat adaptation prevention
observational study on the prophylactic use of curosurf in neonatal respiratory distress syndrome (rds)

Conditions: Respiratory Distress Syndrome, Newborn

Summary: the aim of alizé is to describe a population of premature babies (gestational age (ga) \< 32 weeks) in real life situation and the management of rds.

description includes gestational age, birth clinical characteristics in particular the respiratory function, evaluation of the mother prenatal corticosteroids treatment in prophylaxis of rds, mother medical and obstetric history, premature babies care in the delivery room with a special focus on the curosurf use: prophylactic or curative use / other surfactant / no surfactant. a special focus is on the prophylactic use.

Eligibility criteria:
inclusion criteria: * during the study, each neonatologist will have to include all the babies born with a gestational age \< 32 ga exclusion criteria: * gestational age \> 32 ga * no consent to the data collection by one of the parents

Keywords: pulmonary surfactant respiratory distress syndrome newborn prophylaxis